<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338921</url>
  </required_header>
  <id_info>
    <org_study_id>Triple_3</org_study_id>
    <nct_id>NCT02338921</nct_id>
  </id_info>
  <brief_title>Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy</brief_title>
  <official_title>Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in
      type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two
      drug combination therapy with glimepiride and metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual combination therapy with metformin and sulphonylurea is the most commonly used
      combination regimen to treat patients with type 2 diabetes. But, treatment with the dual
      combination therapy is often unsuccessful at achieving glycaemic control in patients with
      type 2 diabetes.

      Recently, various oral hypoglycemic agents were developed including dipeptidyl peptidase
      (DPP)-IV inhibitor, sodium-glucose cotransporter 2 (SGLT2) inhibitor and new peroxisome
      proliferator-activated receptors (PPARs) agonists.

      But, there have been few studies about the glucose lowering effect of these drugs in Type 2
      diabetes patients on the dual combination therapy with a sulfonylurea agent and metformin.

      Hence, the researchers plan to investigate the efficacy and safety of these drugs in
      combination with a sulfonylurea agent and metformin in type 2 diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic target goal achievement rate</measure>
    <time_frame>24 months</time_frame>
    <description>HbA1c&lt; 7.0% without hypoglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-cell function</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>Beta-cell function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood sugar (FBS) and Post Prandial 2 hour blood glucose (PP2)</measure>
    <time_frame>3,6,9,12,16,20 and 24months</time_frame>
    <description>Fasting blood sugar (FBS) and Post Prandial 2 hour blood glucose (PP2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>3,6,9,12,16,20 and 24months</time_frame>
    <description>Lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>6,12 and 24 months</time_frame>
    <description>Body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine microalbumin to creatinine ratio</measure>
    <time_frame>6,12 and 24 months</time_frame>
    <description>urine microalbumin to creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>3,6,9,12,16,20 and 24months</time_frame>
    <description>Change of HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic target goal achievement rate</measure>
    <time_frame>12 months</time_frame>
    <description>HbA1c&lt; 7.0% without hypoglycemia</description>
  </secondary_outcome>
  <other_outcome>
    <measure>hypoglycemia</measure>
    <time_frame>3,6,9,12,16,20 and 24months</time_frame>
    <description>hypoglycemia</description>
  </other_outcome>
  <other_outcome>
    <measure>body weight change</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>body weight change</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Glimepirde, Metformin, Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dipeptidyl peptidase-4 (DPP4) inhibitor
Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepirde, Metformin, Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Dapagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepirde, Metformin, Lobeglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peroxisome proliferator-activated receptor gamma agonist
Lobeglitazone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg qd per oral during 24months
compared with other treatment groups</description>
    <arm_group_label>Glimepirde, Metformin, Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10mg qd per oral during 24months
compared with other treatment groups</description>
    <arm_group_label>Glimepirde, Metformin, Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobeglitazone</intervention_name>
    <description>0.5mg qd per oral during 24months
compared with other treatment groups</description>
    <arm_group_label>Glimepirde, Metformin, Lobeglitazone</arm_group_label>
    <other_name>Duvie</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepirde</intervention_name>
    <arm_group_label>Glimepirde, Metformin, Sitagliptin</arm_group_label>
    <arm_group_label>Glimepirde, Metformin, Dapagliflozin</arm_group_label>
    <arm_group_label>Glimepirde, Metformin, Lobeglitazone</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Glimepirde, Metformin, Sitagliptin</arm_group_label>
    <arm_group_label>Glimepirde, Metformin, Dapagliflozin</arm_group_label>
    <arm_group_label>Glimepirde, Metformin, Lobeglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 ≤ Age &lt; 80 years

          -  HbA1c ≥ 7 %

          -  combination therapy with glimepiride and metformin over 2 months.

          -  dosage of glimepiride : 1-8mg/day

          -  dosage of metformin : 500-2550mg/day

        Exclusion Criteria:

          -  Type 1 diabetes, gestational diabetes, or secondary forms of diabetes

          -  Contraindication to sitagliptin or dapagliflozin or lobeglitazone

          -  Pregnant or breast feeding women

          -  Medication which affect glycemic control (ex. steroid)

          -  Disease which affect efficacy and safety of drugs

          -  Any major illness (Liver disease, Renal failure, Heart disease, Cancer, etc)

          -  Not appropriate for oral antidiabetic agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNUBH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soo Lim, MD, PHD</last_name>
    <phone>82-31-787-7035</phone>
    <email>limsoo@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Hwa Lee, MD</last_name>
    <phone>82-31-787-6239</phone>
    <email>roroko@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soo Lim</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Hwa Lee, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>triple combination therapy</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>lobeglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

